Guardant Health (NASDAQ:GH) released its earnings results on Monday. The company reported ($1.94) EPS for the quarter, missing the consensus estimate of ($0.29) by ($1.65), Briefing.com reports. The company had revenue of $21.70 million during the quarter, compared to analyst estimates of $17.44 million. The firm’s revenue was up 95.5% on a year-over-year basis. Guardant Health updated its FY 2018 guidance to EPS.

GH stock opened at $33.62 on Tuesday. Guardant Health has a twelve month low of $27.04 and a twelve month high of $44.25.

A number of equities research analysts have commented on GH shares. Leerink Swann reissued an “outperform” rating on shares of Guardant Health in a research note on Monday, October 29th. William Blair started coverage on Guardant Health in a research note on Monday, October 29th. They issued an “outperform” rating for the company. Cowen started coverage on Guardant Health in a research note on Monday, October 29th. They issued an “outperform” rating for the company. Bank of America started coverage on Guardant Health in a research note on Monday, October 29th. They issued a “neutral” rating and a $37.00 price objective for the company. Finally, JPMorgan Chase & Co. started coverage on Guardant Health in a research note on Monday, October 29th. They issued an “overweight” rating and a $42.00 price objective for the company. One analyst has rated the stock with a hold rating and four have issued a buy rating to the company’s stock. Guardant Health currently has an average rating of “Buy” and a consensus target price of $39.50.

ILLEGAL ACTIVITY NOTICE: “Guardant Health (GH) Issues Quarterly Earnings Results, Misses Expectations By $1.65 EPS” was originally published by Daily Political and is the sole property of of Daily Political. If you are reading this piece of content on another domain, it was illegally copied and republished in violation of United States & international trademark and copyright law. The correct version of this piece of content can be read at https://www.dailypolitical.com/2018/11/20/guardant-health-gh-issues-quarterly-earnings-results-misses-expectations-by-1-65-eps.html.

Guardant Health Company Profile

Guardant Health, Inc, a precision oncology company, provides non-invasive cancer diagnostics. It offers liquid biopsy tests for advanced stage cancer, such as Guardant360, a molecular diagnostic test that measures various cancer-related genes from circulating tumor DNA (ctDNA); and GuardantOMNI, a broader panel measuring various genes from ctDNA.

Featured Story: Dow Jones Industrial Average (DJIA)

Receive News & Ratings for Guardant Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Guardant Health and related companies with MarketBeat.com's FREE daily email newsletter.